|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2,202.20 - 2,264.75|
|52 Week Range||1,901.65 - 3,394.95|
|PE Ratio (TTM)||19.14|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aurigene Discovery Technologies Limited, a wholly owned subsidiary of Dr. Reddy’s Laboratories Ltd. and a specialized biotechnology company engaged in discovery and early clinical development of novel and best-in-class therapies to treat cancer and inflammatory diseases, today announced plans to initiate a Phase 2 trial of CA-170, a PDL1-VISTA inhibitor to be conducted at sites in India.
Dr. Reddy’s Laboratories Ltd. announced that the Company will be present at the Morgan Stanley 15th Annual Global Healthcare Conference on Tuesday, September 12th, 2017, in New York City.
Dr. Reddy’s Laboratories Ltd. announced today that it has launched Bupropion Hydrochloride Extended-Release Tablets, USP , 150 mg and 300 mg, a therapeutic equivalent generic version of Wellbutrin XL® Tablets, approved by the U.S.